Get started
Author

Anna Vassall

Observed names: A Vassall, A. Vassall, Anna Vassal, Anna Vassall (144677), Vassal A,, Vassal, A., Vassall Anna, Vassall, A, Vassall, A., Vassall, Anna
Observed institutions: University of London, Stellenbosch University, Royal Tropical Institute, Amsterdam UMC Location University of Amsterdam, Sanofi (France), National Institute for Health and Care Research, Department of Disease Control, London School of Hygiene & Tropical Medicine, Africa Centres for Disease Control and Prevention, World Health Organization, Faculty of Public Health, Amsterdam Institute for Global Health and Development, Health Data Research UK, KNCV TB Plus, University of Amsterdam
ORCID: 0000-0002-2911-1375
Observed ORCID: 0000-0002-2911-1375
OpenAlex ID: A5011782450
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
2019 · Michael J A Reid, Nimalan Arinaminpathy, et al. · The Lancet · 362
PDF
The impact of COVID-19 on TB: a review of the data
2021 · C. F. McQuaid, A. Vassall, et al. · The International Journal of Tuberculosis and Lung Disease · 319
Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis
2011 · Anna Vassall, Sanne van Kampen, et al. · PLoS Medicine · 313
PDF
The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies
2013 · Gabriela B. Gomez, Annick Borquez, et al. · PLoS Medicine · 239
PDF
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF
2015 · Gavin J Churchyard, Wendy S Stevens, et al. · The Lancet Global Health · 209
PDF
Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models
2016 · Rein M G J Houben, Nicolas A Menzies, et al. · The Lancet Global Health · 196
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries
2014 · Gwenan M. Knight, Ulla K. Griffiths, et al. · Proceedings of the National Academy of Sciences · 190
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
2021 · Frank G Sandmann, Nicholas G Davies, et al. · The Lancet Infectious Diseases · 176
PDF
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review
2015 · Yoko V. Laurence, Ulla K. Griffiths, et al. · PharmacoEconomics · 173
PDF
The economic burden of TB diagnosis and treatment in South Africa
2015 · Nicola Foster, Anna Vassall, et al. · Social Science & Medicine · 162
PDF
Reference case for estimating the costs of global health services and Interventions
2017 · Anna Vassall, Sedona Sweeney, et al. · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · 154
PDF
Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience
2011 · Sedona Sweeney, Carol Dayo Obure, et al. · Sexually Transmitted Infections · 139
PDF
Using Top‐down and Bottom‐up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale
2016 · Lucy Cunnama, Edina Sinanovic, et al. · Health Economics · 135
PDF
Tropical Diseases Targeted for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy
2006 · J Remme, Piet Feenstra, et al. · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · 127
Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis
2012 · Andrea Pantoja, Christopher Fitzpatrick, et al. · European Respiratory Journal · 105
PDF
Valuing the work of unpaid community health workers and exploring the incentives to volunteering in rural Africa
2015 · Frida Kasteng, Stella Settumba, et al. · Health Policy and Planning · 96
PDF
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models
2016 · Nicolas A Menzies, Gabriela B Gomez, et al. · The Lancet Global Health · 92
PDF
Count the cost of disability caused by COVID-19
2021 · Andrew Briggs, Anna Vassall · Nature · 89
PDF
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
2023 · Michael Reid, Yvan Jean Patrick Agbassi, et al. · The Lancet · 87
Tuberculosis
2017 · Barry R. Bloom, Rifat Atun, et al. · World Bank, Washington, DC eBooks · 86
The growing burden of noncommunicable disease among persons living with HIV in Zimbabwe
2018 · Mikaela Smit, Jack Olney, et al. · AIDS · 84
Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries
2014 · Mariana Siapka, Michelle Remme, et al. · Bulletin of the World Health Organization · 84
PDF
What next after GDP-based cost-effectiveness thresholds?
2020 · Y-Ling Chi, Mark Blecher, et al. · Gates Open Research · 77
PDF
Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile HIV Service in Cape Town, South Africa: A Cross-sectional Study
2012 · Katharina Kranzer, Stephen D. Lawn, et al. · PLoS Medicine · 77
PDF
Financing intersectoral action for health: a systematic review of co-financing models
2019 · Finn McGuire, Lavanya Vijayasingham, et al. · Globalization and Health · 74
PDF
Works count: 379
Citation count: 7,999
H-index: 48
I10-index: 149
Year
Topic
Type